Table 3.
Summary of highest-grade AEs in patients receiving xaluritamig including most common TRAEs (≥20%).
| Low-dose cohorts | High-dose cohorts | ||
|---|---|---|---|
| All cohorts | (1–7a) | (7b–13) | |
| (N = 97) | (n = 45) | (n = 52) | |
| Patients with any TEAE, n (%) | 97 (100) | 45 (100) | 52 (100) |
| Related to xaluritamig | 94 (97) | 43 (96) | 51 (98) |
| Leading to discontinuation from xaluritamig | 18 (19) | 10 (22) | 8 (15) |
| Leading to xaluritamig dose interruption | 46 (47) | 17 (38) | 29 (56) |
| Leading to xaluritamig dose reduction | 7 (7) | 0 | 7 (13) |
| Serious TEAE | 55 (57) | 23 (51) | 32 (62) |
| Serious TEAE related to xaluritamig | 38 (39) | 16 (36) | 22 (42) |
| All grades | Grade ≥3 | All grades | Grade ≥3 | All grades | Grade ≥3 | |
|---|---|---|---|---|---|---|
| Most common TRAEs (≥20%), n (%) | 94 (97) | 53 (55) | 43 (96) | 24 (53) | 51 (98) | 29 (56) |
| CRS (Lee et al., 2014; ref. 32) | 70 (72) | 2 (2) | 27 (60) | 2 (4) | 43 (83) | 0 |
| Fatigue | 44 (45) | 11 (11) | 21 (47) | 6 (13) | 23 (44) | 5 (10) |
| Myalgia | 33 (34) | 12 (12) | 11 (24) | 4 (9) | 22 (42) | 8 (15) |
| Pyrexia | 31 (32) | 0 | 10 (22) | 0 | 21 (40) | 0 |
| Rash | 27 (28) | 0 | 8 (18) | 0 | 19 (37) | 0 |
| Decreased appetite | 24 (25) | 0 | 8 (18) | 0 | 16 (31) | 0 |
| Arthralgia | 23 (24) | 7 (7) | 9 (20) | 1 (2) | 14 (27) | 6 (12) |
| Anemia | 20 (21) | 13 (13) | 8 (18) | 5 (11) | 12 (23) | 8 (15) |